Linezolid (INN) (IPA: ) is a synthetic antibiotic, the first of the oxazolidinone class, used for the treatment of infections caused by multi-resistant bacteria including methicillin-resistant Staphylococcus aureus (MRSA). It is marketed under the trade name Zyvox (Pfizer).
It was the first commercially available oxazolidinone antibiotic and is usually reserved for the treatment of serious bacterial infections where older antibiotics have failed due to antibiotic resistance. Conditions such as skin infections or nosocomial pneumonia where methicillin or penicillin resistance is found are indicators for linezolid use. Compared to the older antibiotics it is quite expensive.
The drug works by inhibiting the initiation of bacterial protein synthesis; it is the only antibiotic to work in this manner. That and its synthetic nature raised hopes that bacteria would be unable to develop resistance to it and also remove the chance of cross-resistance. (However, in 2003 Staphylococcus aureus was first identified as being resistant to linezolid.) Linezolid is effective against gram-positive pathogens, notably Enterococcus faecium, Staphylococcus aureus, Streptococcus agalactiae, Streptococcus pneumoniae, and Streptococcus pyogenes. It has almost no effect on gram-negative bacteria and is only bacteriostatic against most Enterococcus species.
More on [ Linezolid ]
Antibiotics :: Drugs and Medications

DrugDigest: Linezolid ( Zyvox ) - Information on dosage, usage, side effects, interactions, and drug comparisons, including generics when available.
MEDLINEplus: Linezolid - Features information about dosage, usage, and side effects.
Meta Description: [ Linezolid(Systemic) ]
Zyvox - Antibiotic information from Pharmacia, the manufacturers of this product.
Meta Description: [ ZYVOX.com is the official Web site where healthcare professionals can access clinical information and data about ZYVOX® (linezolid). ]
| New Safety Concerns about Zyvox (June 2007) | |